CLOT Session at the BSH Annual Meeting 2016


The first CLOT session at the British Society of Haematology Annual Scientific Meeting was held on the 19th April 2016 and featured presentations on real world data on the use of DOAC's, how long to anticoagulate post unprovoked VTE, a comparison of risk factors for community and hospital acquired thrombosis with a five year follow up looking at recurrence and mortality and limited vs whole leg scanning. The session proved very popular as we not only filled the room we were using but also an overflow room next door. We are hopeful that we will be invited back to present at next years meeting in Brighton in March 2017 and should know before our annual meeting.

Praxbind® (idarucizumab) licensed in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

  1. Idarucizumab is the first specific reversal agent for a NOAC to receive European licence1
  2. Idarucizumab immediately reverses the anticoagulant effect of dabigatran2-4

Bracknell, United Kingdom - 26th November 2015 – The European Commission has licensed Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding.1 Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be granted a licence in the European Union.1

Continue Reading

Award Success for new CLOT Secretary

New CLOT secretary Jodie Williams was part of the AF and Stroke Prevention  team that won an Innovation award for 2015. Congratulations from all at CLOT



Save The Date CLOT Conference 2016

Following another successful conference CLOT are always looking to the future. The date for the conference in 2016 will be Friday 14/10/16 more details to follow.